Shares of Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) traded down 2.5% during mid-day trading on Friday . The company traded as low as $22.16 and last traded at $22.17, with a volume of 102,815 shares trading hands. The stock had previously closed at $22.73.

A number of analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. JMP Securities lowered shares of Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 28th. Finally, Vetr lowered shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $35.45 target price for the company. in a research note on Monday, April 25th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $28.58.

The firm has a 50 day moving average price of $22.95 and a 200-day moving average price of $26.45. The firm has a market capitalization of $420.09 million and a P/E ratio of 13.03.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, May 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by $0.19. The business earned $13 million during the quarter, compared to analyst estimates of $16.80 million. During the same period in the previous year, the business earned $1.49 earnings per share. The firm’s revenue was down 77.4% on a year-over-year basis. On average, equities research analysts anticipate that Enanta Pharmaceuticals Inc. will post $1.00 EPS for the current year.

Several hedge funds have modified their holdings of ENTA. EQIS Capital Management increased its stake in shares of Enanta Pharmaceuticals by 382.0% in the fourth quarter. EQIS Capital Management now owns 44,836 shares of the company’s stock worth $1,480,000 after buying an additional 35,534 shares during the last quarter. First Trust Advisors LP acquired a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth about $1,374,000. New York State Common Retirement Fund increased its stake in shares of Enanta Pharmaceuticals by 8.0% in the fourth quarter. New York State Common Retirement Fund now owns 133,569 shares of the company’s stock worth $4,410,000 after buying an additional 9,871 shares during the last quarter. GSA Capital Partners LLP increased its stake in shares of Enanta Pharmaceuticals by 44.3% in the fourth quarter. GSA Capital Partners LLP now owns 80,322 shares of the company’s stock worth $2,652,000 after buying an additional 24,670 shares during the last quarter. Finally, Cornerstone Capital Management Holdings LLC. increased its stake in shares of Enanta Pharmaceuticals by 114.7% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 32,851 shares of the company’s stock worth $1,085,000 after buying an additional 17,551 shares during the last quarter.

Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.